Millennium Management LLC bought a new position in shares of Theravance Biopharma (NASDAQ:TBPH) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 15,038 shares of the biopharmaceutical company’s stock, valued at approximately $419,000.
Other institutional investors also recently bought and sold shares of the company. Landscape Capital Management L.L.C. acquired a new position in shares of Theravance Biopharma during the 4th quarter worth about $313,000. Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma during the 4th quarter worth about $416,000. Virtus Fund Advisers LLC acquired a new position in shares of Theravance Biopharma during the 4th quarter worth about $974,000. Alps Advisors Inc. grew its position in shares of Theravance Biopharma by 13.1% during the 4th quarter. Alps Advisors Inc. now owns 59,951 shares of the biopharmaceutical company’s stock worth $1,672,000 after buying an additional 6,938 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Theravance Biopharma by 82.4% in the 4th quarter. Deutsche Bank AG now owns 108,750 shares of the biopharmaceutical company’s stock valued at $3,031,000 after purchasing an additional 49,137 shares during the period. Institutional investors own 84.85% of the company’s stock.
TBPH has been the subject of several research analyst reports. BidaskClub upgraded Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 20th. Leerink Swann boosted their price objective on Theravance Biopharma from $45.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research report on Tuesday, February 27th. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Finally, Piper Jaffray reiterated an “overweight” rating and issued a $45.00 price objective on shares of Theravance Biopharma in a research report on Thursday, March 29th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $39.29.
Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.26) by $0.04. The firm had revenue of $8.32 million for the quarter, compared to analysts’ expectations of $5.74 million. Theravance Biopharma had a negative return on equity of 188.96% and a negative net margin of 1,383.47%. equities analysts forecast that Theravance Biopharma will post -4.8 EPS for the current year.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.